Burkina Faso authorities have suspended the Target Malaria project, financed by the Bill & Melinda Gates Foundation, the Ministry of Higher Education, Scientific Research and Innovation announced in a statement signed by Secretary General Samuel Paré.
What happened
- The ministry ordered a nationwide halt to all activities under the Target Malaria initiative.
- In July, the National Biosafety Agency (ANB) and the National Agency for Environmental Assessment (ANEVE) authorized a limited release of genetically modified male mosquitoes. A first small-scale release took place on 11 August in the village of Surukodingan.
- On 18 August authorities demanded an immediate stop to all work. Samples have been secured and are being prepared for destruction.
About Target Malaria and the controversy
- Target Malaria researches genetic approaches to reduce malaria transmission by releasing genetically modified male mosquitoes that reduce wild mosquito populations or bias offspring.
- The Gates-funded foundation has supported malaria control in Africa for decades, including vaccines and bed net distribution. The World Health Organization has described gene-drive and related genetically modified mosquito technologies as promising but still experimental.
- Critics raise concerns about ecological impacts, long-term risks, regulatory oversight and ethical questions, including fears the program could be misused for population control—claims that program proponents reject.
Context and implications
- Suspension may delay or halt planned trials and slow evaluation of genetic vector-control methods in Burkina Faso.
- Authorities' decision reflects regulatory, ethical and public-safety caution in deploying novel biotechnology in complex ecological and social settings.
- Next steps to watch for include official investigations, environmental and biosafety reviews, consultations with local communities, potential independent risk assessments, and decisions on whether the project will resume, be modified, or be terminated.
Broader relevance
- The case highlights tensions between innovation in disease control and precautionary governance. Outcomes in Burkina Faso could influence regulatory approaches and public acceptance of genetically based vector-control projects elsewhere in the Sahel and Africa.
